01/18/2026
New data in Arthritis & Rheumatology shows subcutaneous anifrolumab is as effective as IV for moderate-to-severe SLE, opening the door to more flexible, at-home treatment options for patients. Read more:
A new study published in Arthritis & Rheumatology demonstrates that subcutaneous administration of anifrolumab provides efficacy comparable to intravenous administration, offering a promising alternative for at-home care of patients living with moderate-to-severe systemic lupus erythematosus.